Vicarious Surgical Inc.
Vicarious Surgical Inc. RBOT Peers
See (RBOT) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RBOT | $8.07 | +2.15% | 47.5M | -0.77 | -$10.44 | N/A |
| ABT | $131.76 | -1.10% | 232.4B | 17.37 | $7.69 | +1.71% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| BSX | $103.37 | +0.40% | 153.6B | 75.81 | $1.37 | N/A |
| SYK | $388.91 | -0.80% | 150.9B | 53.34 | $7.40 | +0.84% |
| MDT | $89.87 | +0.98% | 114.5B | 24.76 | $3.61 | +3.92% |
| EW | $77.74 | +0.71% | 46.2B | 32.55 | $2.42 | N/A |
| DXCM | $83.32 | -1.83% | 33.5B | 64.26 | $1.33 | N/A |
| PHG | $24.02 | -0.46% | 22.8B | 79.58 | $0.31 | +3.60% |
| STE | $227.90 | -1.46% | 22.7B | 37.44 | $6.16 | +1.21% |
Stock Comparison
RBOT vs ABT Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, ABT has a market cap of 232.4B. Regarding current trading prices, RBOT is priced at $8.07, while ABT trades at $131.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas ABT's P/E ratio is 17.37. In terms of profitability, RBOT's ROE is -1.17%, compared to ABT's ROE of +0.31%. Regarding short-term risk, RBOT is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs BSX-PA Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, RBOT is priced at $8.07, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, RBOT's ROE is -1.17%, compared to BSX-PA's ROE of +0.10%. Regarding short-term risk, RBOT is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs BSX Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, BSX has a market cap of 153.6B. Regarding current trading prices, RBOT is priced at $8.07, while BSX trades at $103.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas BSX's P/E ratio is 75.81. In terms of profitability, RBOT's ROE is -1.17%, compared to BSX's ROE of +0.10%. Regarding short-term risk, RBOT is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs SYK Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, SYK has a market cap of 150.9B. Regarding current trading prices, RBOT is priced at $8.07, while SYK trades at $388.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas SYK's P/E ratio is 53.34. In terms of profitability, RBOT's ROE is -1.17%, compared to SYK's ROE of +0.11%. Regarding short-term risk, RBOT is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs MDT Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, MDT has a market cap of 114.5B. Regarding current trading prices, RBOT is priced at $8.07, while MDT trades at $89.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas MDT's P/E ratio is 24.76. In terms of profitability, RBOT's ROE is -1.17%, compared to MDT's ROE of +0.10%. Regarding short-term risk, RBOT is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs EW Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, EW has a market cap of 46.2B. Regarding current trading prices, RBOT is priced at $8.07, while EW trades at $77.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas EW's P/E ratio is 32.55. In terms of profitability, RBOT's ROE is -1.17%, compared to EW's ROE of +0.49%. Regarding short-term risk, RBOT is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs DXCM Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, DXCM has a market cap of 33.5B. Regarding current trading prices, RBOT is priced at $8.07, while DXCM trades at $83.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas DXCM's P/E ratio is 64.26. In terms of profitability, RBOT's ROE is -1.17%, compared to DXCM's ROE of +0.24%. Regarding short-term risk, RBOT is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs PHG Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, PHG has a market cap of 22.8B. Regarding current trading prices, RBOT is priced at $8.07, while PHG trades at $24.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas PHG's P/E ratio is 79.58. In terms of profitability, RBOT's ROE is -1.17%, compared to PHG's ROE of +0.03%. Regarding short-term risk, RBOT is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs STE Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, STE has a market cap of 22.7B. Regarding current trading prices, RBOT is priced at $8.07, while STE trades at $227.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas STE's P/E ratio is 37.44. In terms of profitability, RBOT's ROE is -1.17%, compared to STE's ROE of +0.09%. Regarding short-term risk, RBOT is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs PODD Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, PODD has a market cap of 20.9B. Regarding current trading prices, RBOT is priced at $8.07, while PODD trades at $291.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas PODD's P/E ratio is 54.19. In terms of profitability, RBOT's ROE is -1.17%, compared to PODD's ROE of +0.35%. Regarding short-term risk, RBOT is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs ZBH Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, ZBH has a market cap of 18.8B. Regarding current trading prices, RBOT is priced at $8.07, while ZBH trades at $93.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas ZBH's P/E ratio is 21.14. In terms of profitability, RBOT's ROE is -1.17%, compared to ZBH's ROE of +0.07%. Regarding short-term risk, RBOT is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs ABMD Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, RBOT is priced at $8.07, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas ABMD's P/E ratio is 65.36. In terms of profitability, RBOT's ROE is -1.17%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, RBOT is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs ALGN Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, ALGN has a market cap of 14.8B. Regarding current trading prices, RBOT is priced at $8.07, while ALGN trades at $201.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas ALGN's P/E ratio is 37.24. In terms of profitability, RBOT's ROE is -1.17%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, RBOT is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs SNN Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, SNN has a market cap of 13.6B. Regarding current trading prices, RBOT is priced at $8.07, while SNN trades at $30.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas SNN's P/E ratio is 33.05. In terms of profitability, RBOT's ROE is -1.17%, compared to SNN's ROE of +0.08%. Regarding short-term risk, RBOT is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs SWAV Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, RBOT is priced at $8.07, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas SWAV's P/E ratio is 78.76. In terms of profitability, RBOT's ROE is -1.17%, compared to SWAV's ROE of +0.14%. Regarding short-term risk, RBOT is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs PEN Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, PEN has a market cap of 9.4B. Regarding current trading prices, RBOT is priced at $8.07, while PEN trades at $237.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas PEN's P/E ratio is 225.76. In terms of profitability, RBOT's ROE is -1.17%, compared to PEN's ROE of +0.04%. Regarding short-term risk, RBOT is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs GMED Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, GMED has a market cap of 7.8B. Regarding current trading prices, RBOT is priced at $8.07, while GMED trades at $57.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas GMED's P/E ratio is 42.79. In terms of profitability, RBOT's ROE is -1.17%, compared to GMED's ROE of +0.05%. Regarding short-term risk, RBOT is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs BIO Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, BIO has a market cap of 7.1B. Regarding current trading prices, RBOT is priced at $8.07, while BIO trades at $258.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas BIO's P/E ratio is -3.40. In terms of profitability, RBOT's ROE is -1.17%, compared to BIO's ROE of -0.32%. Regarding short-term risk, RBOT is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs BIO-B Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, BIO-B has a market cap of 6.8B. Regarding current trading prices, RBOT is priced at $8.07, while BIO-B trades at $250.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas BIO-B's P/E ratio is -3.27. In terms of profitability, RBOT's ROE is -1.17%, compared to BIO-B's ROE of -0.32%. Regarding short-term risk, RBOT is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs BRKR Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, BRKR has a market cap of 6.6B. Regarding current trading prices, RBOT is priced at $8.07, while BRKR trades at $44.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas BRKR's P/E ratio is 83.81. In terms of profitability, RBOT's ROE is -1.17%, compared to BRKR's ROE of +0.04%. Regarding short-term risk, RBOT is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs GKOS Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, GKOS has a market cap of 6.1B. Regarding current trading prices, RBOT is priced at $8.07, while GKOS trades at $104.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas GKOS's P/E ratio is -46.94. In terms of profitability, RBOT's ROE is -1.17%, compared to GKOS's ROE of -0.17%. Regarding short-term risk, RBOT is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs NARI Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, RBOT is priced at $8.07, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas NARI's P/E ratio is -59.24. In terms of profitability, RBOT's ROE is -1.17%, compared to NARI's ROE of -0.18%. Regarding short-term risk, RBOT is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs IRTC Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, IRTC has a market cap of 4.3B. Regarding current trading prices, RBOT is priced at $8.07, while IRTC trades at $135.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas IRTC's P/E ratio is -43.23. In terms of profitability, RBOT's ROE is -1.17%, compared to IRTC's ROE of -1.13%. Regarding short-term risk, RBOT is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs ITGR Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, RBOT is priced at $8.07, while ITGR trades at $119.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas ITGR's P/E ratio is 56.93. In terms of profitability, RBOT's ROE is -1.17%, compared to ITGR's ROE of +0.05%. Regarding short-term risk, RBOT is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs TMDX Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, TMDX has a market cap of 4.2B. Regarding current trading prices, RBOT is priced at $8.07, while TMDX trades at $114.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas TMDX's P/E ratio is 87.87. In terms of profitability, RBOT's ROE is -1.17%, compared to TMDX's ROE of +0.22%. Regarding short-term risk, RBOT is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for RBOT.
RBOT vs INSP Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, INSP has a market cap of 4.1B. Regarding current trading prices, RBOT is priced at $8.07, while INSP trades at $132.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas INSP's P/E ratio is 63.89. In terms of profitability, RBOT's ROE is -1.17%, compared to INSP's ROE of +0.10%. Regarding short-term risk, RBOT is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for RBOT.
RBOT vs AXNX Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, RBOT is priced at $8.07, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas AXNX's P/E ratio is -709.80. In terms of profitability, RBOT's ROE is -1.17%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, RBOT is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs PRCT Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, PRCT has a market cap of 3.3B. Regarding current trading prices, RBOT is priced at $8.07, while PRCT trades at $57.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas PRCT's P/E ratio is -34.99. In terms of profitability, RBOT's ROE is -1.17%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, RBOT is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for RBOT.
RBOT vs LIVN Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, LIVN has a market cap of 2.5B. Regarding current trading prices, RBOT is priced at $8.07, while LIVN trades at $44.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas LIVN's P/E ratio is -11.47. In terms of profitability, RBOT's ROE is -1.17%, compared to LIVN's ROE of -0.18%. Regarding short-term risk, RBOT is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs NUVA Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, RBOT is priced at $8.07, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas NUVA's P/E ratio is 75.00. In terms of profitability, RBOT's ROE is -1.17%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, RBOT is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs UFPT Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, UFPT has a market cap of 1.9B. Regarding current trading prices, RBOT is priced at $8.07, while UFPT trades at $244.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas UFPT's P/E ratio is 30.95. In terms of profitability, RBOT's ROE is -1.17%, compared to UFPT's ROE of +0.19%. Regarding short-term risk, RBOT is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for RBOT.
RBOT vs ATEC Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, ATEC has a market cap of 1.7B. Regarding current trading prices, RBOT is priced at $8.07, while ATEC trades at $11.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas ATEC's P/E ratio is -10.16. In terms of profitability, RBOT's ROE is -1.17%, compared to ATEC's ROE of -2.58%. Regarding short-term risk, RBOT is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for RBOT.
RBOT vs CNMD Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, CNMD has a market cap of 1.7B. Regarding current trading prices, RBOT is priced at $8.07, while CNMD trades at $51.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas CNMD's P/E ratio is 14.08. In terms of profitability, RBOT's ROE is -1.17%, compared to CNMD's ROE of +0.13%. Regarding short-term risk, RBOT is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for RBOT.
RBOT vs AORT Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, AORT has a market cap of 1.4B. Regarding current trading prices, RBOT is priced at $8.07, while AORT trades at $31.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas AORT's P/E ratio is -63.97. In terms of profitability, RBOT's ROE is -1.17%, compared to AORT's ROE of -0.07%. Regarding short-term risk, RBOT is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for RBOT.
RBOT vs ESTA Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, ESTA has a market cap of 1.3B. Regarding current trading prices, RBOT is priced at $8.07, while ESTA trades at $45.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas ESTA's P/E ratio is -14.71. In terms of profitability, RBOT's ROE is -1.17%, compared to ESTA's ROE of -2.10%. Regarding short-term risk, RBOT is more volatile compared to ESTA. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs HSKA Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, RBOT is priced at $8.07, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas HSKA's P/E ratio is -62.49. In terms of profitability, RBOT's ROE is -1.17%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, RBOT is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs AHCO Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, AHCO has a market cap of 1.3B. Regarding current trading prices, RBOT is priced at $8.07, while AHCO trades at $9.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas AHCO's P/E ratio is 16.26. In terms of profitability, RBOT's ROE is -1.17%, compared to AHCO's ROE of +0.06%. Regarding short-term risk, RBOT is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs SILK Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, RBOT is priced at $8.07, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas SILK's P/E ratio is -18.96. In terms of profitability, RBOT's ROE is -1.17%, compared to SILK's ROE of -0.29%. Regarding short-term risk, RBOT is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs FNA Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, RBOT is priced at $8.07, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas FNA's P/E ratio is -19.83. In terms of profitability, RBOT's ROE is -1.17%, compared to FNA's ROE of -0.36%. Regarding short-term risk, RBOT is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs TNDM Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, RBOT is priced at $8.07, while TNDM trades at $15.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas TNDM's P/E ratio is -5.80. In terms of profitability, RBOT's ROE is -1.17%, compared to TNDM's ROE of -0.83%. Regarding short-term risk, RBOT is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for RBOT.
RBOT vs INMD Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, INMD has a market cap of 1.1B. Regarding current trading prices, RBOT is priced at $8.07, while INMD trades at $14.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas INMD's P/E ratio is 6.80. In terms of profitability, RBOT's ROE is -1.17%, compared to INMD's ROE of +0.25%. Regarding short-term risk, RBOT is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs SSII Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, SSII has a market cap of 1B. Regarding current trading prices, RBOT is priced at $8.07, while SSII trades at $5.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas SSII's P/E ratio is -66.50. In terms of profitability, RBOT's ROE is -1.17%, compared to SSII's ROE of -1.05%. Regarding short-term risk, RBOT is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for RBOT.
RBOT vs IART Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, IART has a market cap of 1B. Regarding current trading prices, RBOT is priced at $8.07, while IART trades at $12.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas IART's P/E ratio is -34.68. In terms of profitability, RBOT's ROE is -1.17%, compared to IART's ROE of -0.03%. Regarding short-term risk, RBOT is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs CSII Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, RBOT is priced at $8.07, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas CSII's P/E ratio is -20.83. In terms of profitability, RBOT's ROE is -1.17%, compared to CSII's ROE of -0.14%. Regarding short-term risk, RBOT is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs SIBN Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, SIBN has a market cap of 800.7M. Regarding current trading prices, RBOT is priced at $8.07, while SIBN trades at $17.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas SIBN's P/E ratio is -29.82. In terms of profitability, RBOT's ROE is -1.17%, compared to SIBN's ROE of -0.16%. Regarding short-term risk, RBOT is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for RBOT.
RBOT vs IRMD Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, IRMD has a market cap of 756.2M. Regarding current trading prices, RBOT is priced at $8.07, while IRMD trades at $58.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas IRMD's P/E ratio is 38.37. In terms of profitability, RBOT's ROE is -1.17%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, RBOT is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs CRY Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, RBOT is priced at $8.07, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas CRY's P/E ratio is 425.71. In terms of profitability, RBOT's ROE is -1.17%, compared to CRY's ROE of -0.07%. Regarding short-term risk, RBOT is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for RBOT.
RBOT vs CBLL Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, CBLL has a market cap of 605.8M. Regarding current trading prices, RBOT is priced at $8.07, while CBLL trades at $16.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas CBLL's P/E ratio is -13.41. In terms of profitability, RBOT's ROE is -1.17%, compared to CBLL's ROE of -1.64%. Regarding short-term risk, RBOT is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for RBOT.
RBOT vs APEN Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, RBOT is priced at $8.07, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas APEN's P/E ratio is -9.43. In terms of profitability, RBOT's ROE is -1.17%, compared to APEN's ROE of -0.85%. Regarding short-term risk, RBOT is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs AVNS Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, AVNS has a market cap of 567M. Regarding current trading prices, RBOT is priced at $8.07, while AVNS trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas AVNS's P/E ratio is -1.48. In terms of profitability, RBOT's ROE is -1.17%, compared to AVNS's ROE of -0.37%. Regarding short-term risk, RBOT is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs KIDS Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, KIDS has a market cap of 556.1M. Regarding current trading prices, RBOT is priced at $8.07, while KIDS trades at $21.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas KIDS's P/E ratio is -12.76. In terms of profitability, RBOT's ROE is -1.17%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, RBOT is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs AXGN Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, AXGN has a market cap of 549.7M. Regarding current trading prices, RBOT is priced at $8.07, while AXGN trades at $11.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas AXGN's P/E ratio is -75.44. In terms of profitability, RBOT's ROE is -1.17%, compared to AXGN's ROE of -0.07%. Regarding short-term risk, RBOT is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for RBOT.
RBOT vs SMLR Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, SMLR has a market cap of 512.9M. Regarding current trading prices, RBOT is priced at $8.07, while SMLR trades at $45.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas SMLR's P/E ratio is -19.24. In terms of profitability, RBOT's ROE is -1.17%, compared to SMLR's ROE of -0.21%. Regarding short-term risk, RBOT is less volatile compared to SMLR. This indicates potentially lower risk in terms of short-term price fluctuations for RBOT.
RBOT vs BVS Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, BVS has a market cap of 491M. Regarding current trading prices, RBOT is priced at $8.07, while BVS trades at $7.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas BVS's P/E ratio is -15.42. In terms of profitability, RBOT's ROE is -1.17%, compared to BVS's ROE of -0.21%. Regarding short-term risk, RBOT is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for RBOT.
RBOT vs BFLY-WT Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, BFLY-WT has a market cap of 478.3M. Regarding current trading prices, RBOT is priced at $8.07, while BFLY-WT trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas BFLY-WT's P/E ratio is N/A. In terms of profitability, RBOT's ROE is -1.17%, compared to BFLY-WT's ROE of -0.33%. Regarding short-term risk, RBOT is less volatile compared to BFLY-WT. This indicates potentially lower risk in terms of short-term price fluctuations for RBOT.
RBOT vs BFLY Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, BFLY has a market cap of 463.7M. Regarding current trading prices, RBOT is priced at $8.07, while BFLY trades at $1.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas BFLY's P/E ratio is -6.25. In terms of profitability, RBOT's ROE is -1.17%, compared to BFLY's ROE of -0.33%. Regarding short-term risk, RBOT is more volatile compared to BFLY. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs CTKB Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, CTKB has a market cap of 450.9M. Regarding current trading prices, RBOT is priced at $8.07, while CTKB trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas CTKB's P/E ratio is -39.56. In terms of profitability, RBOT's ROE is -1.17%, compared to CTKB's ROE of -0.03%. Regarding short-term risk, RBOT is more volatile compared to CTKB. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs PACB Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, PACB has a market cap of 450.1M. Regarding current trading prices, RBOT is priced at $8.07, while PACB trades at $1.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas PACB's P/E ratio is -0.54. In terms of profitability, RBOT's ROE is -1.17%, compared to PACB's ROE of -1.70%. Regarding short-term risk, RBOT is more volatile compared to PACB. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs OFIX Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, OFIX has a market cap of 445.1M. Regarding current trading prices, RBOT is priced at $8.07, while OFIX trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas OFIX's P/E ratio is -3.07. In terms of profitability, RBOT's ROE is -1.17%, compared to OFIX's ROE of -0.28%. Regarding short-term risk, RBOT is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs SRDX Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, SRDX has a market cap of 443.7M. Regarding current trading prices, RBOT is priced at $8.07, while SRDX trades at $31.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas SRDX's P/E ratio is -22.16. In terms of profitability, RBOT's ROE is -1.17%, compared to SRDX's ROE of -0.17%. Regarding short-term risk, RBOT is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs TMCI Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, TMCI has a market cap of 391.3M. Regarding current trading prices, RBOT is priced at $8.07, while TMCI trades at $5.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas TMCI's P/E ratio is -7.32. In terms of profitability, RBOT's ROE is -1.17%, compared to TMCI's ROE of -0.49%. Regarding short-term risk, RBOT is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for RBOT.
RBOT vs SENS Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, SENS has a market cap of 377.1M. Regarding current trading prices, RBOT is priced at $8.07, while SENS trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas SENS's P/E ratio is -4.54. In terms of profitability, RBOT's ROE is -1.17%, compared to SENS's ROE of -7.46%. Regarding short-term risk, RBOT is more volatile compared to SENS. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs OM Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, OM has a market cap of 366.1M. Regarding current trading prices, RBOT is priced at $8.07, while OM trades at $19.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas OM's P/E ratio is -0.72. In terms of profitability, RBOT's ROE is -1.17%, compared to OM's ROE of -1.45%. Regarding short-term risk, RBOT is less volatile compared to OM. This indicates potentially lower risk in terms of short-term price fluctuations for RBOT.
RBOT vs VREX Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, VREX has a market cap of 354.4M. Regarding current trading prices, RBOT is priced at $8.07, while VREX trades at $8.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas VREX's P/E ratio is -8.29. In terms of profitability, RBOT's ROE is -1.17%, compared to VREX's ROE of -0.08%. Regarding short-term risk, RBOT is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs RXST Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, RXST has a market cap of 343.8M. Regarding current trading prices, RBOT is priced at $8.07, while RXST trades at $8.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas RXST's P/E ratio is -12.82. In terms of profitability, RBOT's ROE is -1.17%, compared to RXST's ROE of -0.10%. Regarding short-term risk, RBOT is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for RBOT.
RBOT vs CLPT Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, CLPT has a market cap of 338M. Regarding current trading prices, RBOT is priced at $8.07, while CLPT trades at $11.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas CLPT's P/E ratio is -15.74. In terms of profitability, RBOT's ROE is -1.17%, compared to CLPT's ROE of -0.78%. Regarding short-term risk, RBOT is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for RBOT.
RBOT vs NPCE Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, NPCE has a market cap of 333.2M. Regarding current trading prices, RBOT is priced at $8.07, while NPCE trades at $9.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas NPCE's P/E ratio is -12.39. In terms of profitability, RBOT's ROE is -1.17%, compared to NPCE's ROE of -1.40%. Regarding short-term risk, RBOT is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for RBOT.
RBOT vs NNOX Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, NNOX has a market cap of 330M. Regarding current trading prices, RBOT is priced at $8.07, while NNOX trades at $5.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas NNOX's P/E ratio is -5.69. In terms of profitability, RBOT's ROE is -1.17%, compared to NNOX's ROE of -0.31%. Regarding short-term risk, RBOT is more volatile compared to NNOX. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs SNWV Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, SNWV has a market cap of 308.9M. Regarding current trading prices, RBOT is priced at $8.07, while SNWV trades at $35.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas SNWV's P/E ratio is -5.79. In terms of profitability, RBOT's ROE is -1.17%, compared to SNWV's ROE of +1.00%. Regarding short-term risk, RBOT is more volatile compared to SNWV. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs CATX Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, CATX has a market cap of 303.2M. Regarding current trading prices, RBOT is priced at $8.07, while CATX trades at $3.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas CATX's P/E ratio is -3.32. In terms of profitability, RBOT's ROE is -1.17%, compared to CATX's ROE of -0.27%. Regarding short-term risk, RBOT is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for RBOT.
RBOT vs CERS Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, CERS has a market cap of 297.3M. Regarding current trading prices, RBOT is priced at $8.07, while CERS trades at $1.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas CERS's P/E ratio is -15.55. In terms of profitability, RBOT's ROE is -1.17%, compared to CERS's ROE of -0.35%. Regarding short-term risk, RBOT is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for RBOT.
RBOT vs PTHL Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, PTHL has a market cap of 291.3M. Regarding current trading prices, RBOT is priced at $8.07, while PTHL trades at $20.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas PTHL's P/E ratio is -408.80. In terms of profitability, RBOT's ROE is -1.17%, compared to PTHL's ROE of -0.30%. Regarding short-term risk, RBOT is more volatile compared to PTHL. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs VMD Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, VMD has a market cap of 275.9M. Regarding current trading prices, RBOT is priced at $8.07, while VMD trades at $6.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas VMD's P/E ratio is 22.52. In terms of profitability, RBOT's ROE is -1.17%, compared to VMD's ROE of +0.10%. Regarding short-term risk, RBOT is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs ZIMV Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, ZIMV has a market cap of 262.5M. Regarding current trading prices, RBOT is priced at $8.07, while ZIMV trades at $9.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas ZIMV's P/E ratio is -10.22. In terms of profitability, RBOT's ROE is -1.17%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, RBOT is less volatile compared to ZIMV. This indicates potentially lower risk in terms of short-term price fluctuations for RBOT.
RBOT vs MASS Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, MASS has a market cap of 258.6M. Regarding current trading prices, RBOT is priced at $8.07, while MASS trades at $6.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas MASS's P/E ratio is -3.25. In terms of profitability, RBOT's ROE is -1.17%, compared to MASS's ROE of -0.13%. Regarding short-term risk, RBOT is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for RBOT.
RBOT vs MXCT Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, MXCT has a market cap of 243.4M. Regarding current trading prices, RBOT is priced at $8.07, while MXCT trades at $2.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas MXCT's P/E ratio is -5.72. In terms of profitability, RBOT's ROE is -1.17%, compared to MXCT's ROE of -0.20%. Regarding short-term risk, RBOT is more volatile compared to MXCT. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs BWAY Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, BWAY has a market cap of 239.1M. Regarding current trading prices, RBOT is priced at $8.07, while BWAY trades at $12.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas BWAY's P/E ratio is 57.52. In terms of profitability, RBOT's ROE is -1.17%, compared to BWAY's ROE of +0.07%. Regarding short-term risk, RBOT is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs TCMD Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, TCMD has a market cap of 238.5M. Regarding current trading prices, RBOT is priced at $8.07, while TCMD trades at $9.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas TCMD's P/E ratio is 15.55. In terms of profitability, RBOT's ROE is -1.17%, compared to TCMD's ROE of +0.08%. Regarding short-term risk, RBOT is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs QTRX Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, QTRX has a market cap of 227.5M. Regarding current trading prices, RBOT is priced at $8.07, while QTRX trades at $5.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas QTRX's P/E ratio is -4.72. In terms of profitability, RBOT's ROE is -1.17%, compared to QTRX's ROE of -0.15%. Regarding short-term risk, RBOT is more volatile compared to QTRX. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs NVRO Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, RBOT is priced at $8.07, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas NVRO's P/E ratio is -1.91. In terms of profitability, RBOT's ROE is -1.17%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, RBOT is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs EYES Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, RBOT is priced at $8.07, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas EYES's P/E ratio is N/A. In terms of profitability, RBOT's ROE is -1.17%, compared to EYES's ROE of -0.26%. Regarding short-term risk, RBOT is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for RBOT.
RBOT vs INGN Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, INGN has a market cap of 196.5M. Regarding current trading prices, RBOT is priced at $8.07, while INGN trades at $7.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas INGN's P/E ratio is -6.36. In terms of profitability, RBOT's ROE is -1.17%, compared to INGN's ROE of -0.15%. Regarding short-term risk, RBOT is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for RBOT.
RBOT vs TLSI Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, TLSI has a market cap of 189.9M. Regarding current trading prices, RBOT is priced at $8.07, while TLSI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas TLSI's P/E ratio is -4.55. In terms of profitability, RBOT's ROE is -1.17%, compared to TLSI's ROE of +1.04%. Regarding short-term risk, RBOT is more volatile compared to TLSI. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs PROF Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, PROF has a market cap of 182.4M. Regarding current trading prices, RBOT is priced at $8.07, while PROF trades at $5.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas PROF's P/E ratio is -5.02. In terms of profitability, RBOT's ROE is -1.17%, compared to PROF's ROE of -0.70%. Regarding short-term risk, RBOT is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for RBOT.
RBOT vs CVRX Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, CVRX has a market cap of 181.7M. Regarding current trading prices, RBOT is priced at $8.07, while CVRX trades at $6.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas CVRX's P/E ratio is -3.26. In terms of profitability, RBOT's ROE is -1.17%, compared to CVRX's ROE of -0.79%. Regarding short-term risk, RBOT is more volatile compared to CVRX. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs SGHT Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, SGHT has a market cap of 177.6M. Regarding current trading prices, RBOT is priced at $8.07, while SGHT trades at $3.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas SGHT's P/E ratio is -3.51. In terms of profitability, RBOT's ROE is -1.17%, compared to SGHT's ROE of -0.55%. Regarding short-term risk, RBOT is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs ANIK Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, ANIK has a market cap of 169.2M. Regarding current trading prices, RBOT is priced at $8.07, while ANIK trades at $11.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas ANIK's P/E ratio is -15.73. In terms of profitability, RBOT's ROE is -1.17%, compared to ANIK's ROE of -0.33%. Regarding short-term risk, RBOT is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for RBOT.
RBOT vs ELMD Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, ELMD has a market cap of 168.5M. Regarding current trading prices, RBOT is priced at $8.07, while ELMD trades at $19.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas ELMD's P/E ratio is 25.43. In terms of profitability, RBOT's ROE is -1.17%, compared to ELMD's ROE of +0.17%. Regarding short-term risk, RBOT is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs BSGM Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, BSGM has a market cap of 160.4M. Regarding current trading prices, RBOT is priced at $8.07, while BSGM trades at $5.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas BSGM's P/E ratio is -11.08. In terms of profitability, RBOT's ROE is -1.17%, compared to BSGM's ROE of -35.30%. Regarding short-term risk, RBOT is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for RBOT.
RBOT vs RCEL Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, RCEL has a market cap of 157M. Regarding current trading prices, RBOT is priced at $8.07, while RCEL trades at $5.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas RCEL's P/E ratio is -2.71. In terms of profitability, RBOT's ROE is -1.17%, compared to RCEL's ROE of -3.38%. Regarding short-term risk, RBOT is less volatile compared to RCEL. This indicates potentially lower risk in terms of short-term price fluctuations for RBOT.
RBOT vs LNSR Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, LNSR has a market cap of 156.1M. Regarding current trading prices, RBOT is priced at $8.07, while LNSR trades at $13.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas LNSR's P/E ratio is -2.70. In terms of profitability, RBOT's ROE is -1.17%, compared to LNSR's ROE of -5.28%. Regarding short-term risk, RBOT is more volatile compared to LNSR. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs RPID Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, RPID has a market cap of 148.4M. Regarding current trading prices, RBOT is priced at $8.07, while RPID trades at $3.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas RPID's P/E ratio is -3.29. In terms of profitability, RBOT's ROE is -1.17%, compared to RPID's ROE of -0.56%. Regarding short-term risk, RBOT is more volatile compared to RPID. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs OWLT Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, OWLT has a market cap of 145.4M. Regarding current trading prices, RBOT is priced at $8.07, while OWLT trades at $8.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas OWLT's P/E ratio is -5.64. In terms of profitability, RBOT's ROE is -1.17%, compared to OWLT's ROE of +1.25%. Regarding short-term risk, RBOT is less volatile compared to OWLT. This indicates potentially lower risk in terms of short-term price fluctuations for RBOT.
RBOT vs LUCD Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, LUCD has a market cap of 126.6M. Regarding current trading prices, RBOT is priced at $8.07, while LUCD trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas LUCD's P/E ratio is -1.00. In terms of profitability, RBOT's ROE is -1.17%, compared to LUCD's ROE of +26.96%. Regarding short-term risk, RBOT is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for RBOT.
RBOT vs AVR Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, AVR has a market cap of 125.3M. Regarding current trading prices, RBOT is priced at $8.07, while AVR trades at $3.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas AVR's P/E ratio is -0.97. In terms of profitability, RBOT's ROE is -1.17%, compared to AVR's ROE of -2.92%. Regarding short-term risk, RBOT is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for RBOT.
RBOT vs BDMD Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, BDMD has a market cap of 124.4M. Regarding current trading prices, RBOT is priced at $8.07, while BDMD trades at $3.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas BDMD's P/E ratio is 7.11. In terms of profitability, RBOT's ROE is -1.17%, compared to BDMD's ROE of +0.32%. Regarding short-term risk, RBOT is less volatile compared to BDMD. This indicates potentially lower risk in terms of short-term price fluctuations for RBOT.
RBOT vs MGRM Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, MGRM has a market cap of 119.2M. Regarding current trading prices, RBOT is priced at $8.07, while MGRM trades at $3.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas MGRM's P/E ratio is -6.68. In terms of profitability, RBOT's ROE is -1.17%, compared to MGRM's ROE of -1.26%. Regarding short-term risk, RBOT is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs LUNG Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, LUNG has a market cap of 107.1M. Regarding current trading prices, RBOT is priced at $8.07, while LUNG trades at $2.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas LUNG's P/E ratio is -1.85. In terms of profitability, RBOT's ROE is -1.17%, compared to LUNG's ROE of -0.64%. Regarding short-term risk, RBOT is more volatile compared to LUNG. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.
RBOT vs ICAD Comparison
RBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RBOT stands at 47.5M. In comparison, ICAD has a market cap of 106.4M. Regarding current trading prices, RBOT is priced at $8.07, while ICAD trades at $3.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RBOT currently has a P/E ratio of -0.77, whereas ICAD's P/E ratio is -20.39. In terms of profitability, RBOT's ROE is -1.17%, compared to ICAD's ROE of -0.17%. Regarding short-term risk, RBOT is more volatile compared to ICAD. This indicates potentially higher risk in terms of short-term price fluctuations for RBOT.